Indivior Plc

Indivior Plc

INDV

Market Cap$2.89B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Indivior PlcIndivior Plc-10.3-1%1.1-1.2
$13.00

Target Price by Analysts

47.6% upsideIndivior Plc Target Price DetailsTarget Price
$-8.12

Current Fair Value

192.2% downside

Overvalued by 192.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.89 Billion
Enterprise Value$2.99 Billion
Dividend Yield$0 (0%)
Earnings per Share$0.01
Beta0.2
Outstanding Shares134,848,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-10.31
PEG10
Price to Sales1.1
Price to Book Ratio-2.94
Enterprise Value to Revenue2.52
Enterprise Value to EBIT16.42
Enterprise Value to Net Income-1350
Total Debt to Enterprise0.14
Debt to Equity-1.21

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Indivior Plc

CEO: Shaun Thaxter

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...